STAAR Surgical Co

Broadwood’s steady buying of STAAR Surgical shares signals confidence in its safe, FDA‑cleared EDOF lenses—backed by strong 88% success rates—and a projected $650 million U.S. cataract implant revenue in 2027–29, making STAAR a top contender for inv…

Broadwood’s surge in STAAR Surgical shares signals confidence as the company pivots back to high‑margin implantable lenses and glaucoma devices, leveraging FDA approvals and a robust safety record to drive future value.